title: [Anti-angiogenic therapy for gastrointestinal tumours].
abstract: New therapeutic strategies that notably lack cross resistance with established treatment regimens are much needed in gastroenterological oncology. One such approach is therapeutic anti-angiogenesis which aims at the inhibition of vasculature growth in solid tumours. Since numerous gastrointestinal tumours show strong tumour neoangiogenesis and consequently are highly vascularised, anti-angiogenic therapies will play a pivotal role in tomorrow's gastroenterological oncology. Hence, this review covers (i) basic mechanisms of tumour angiogenesis, (ii) recent anti-angiogenic strategies in the field of gastroenterological oncology as well as (iii) a discussion of their current limitations and perspectives.
authors.affiliation: Abteilung Innere Medizin I, Medizinische Universitätsklinik, Tübingen. florian.graepler@uni-tuebingen.de
authors.forename: F
authors.initials: F
authors.lastname: Graepler
authors.forename: M
authors.initials: M
authors.lastname: Gregor
authors.forename: U M
authors.initials: UM
authors.lastname: Lauer
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D000068579:Celecoxib; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004195:Disease Models, Animal; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005260:Female; D005544:Forecasting; D005770:Gastrointestinal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008297:Male; D009389:Neovascularization, Pathologic; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D011230:Precancerous Conditions / Q000517:prevention & control; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011720:Pyrazoles / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D040262:Receptors, Vascular Endothelial Growth Factor; D013449:Sulfonamides / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000097:blood
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D011505:Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; D000068579:Celecoxib